Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded... (GlobeNewswire EN) +++ WAVE LIFE SCIENCES Aktie -3,03%

GlobeNewswire EN Nachrichten

GlobeNewswire verbreitet Pressemeldungen und Pflichtmitteilungen von börsennotierten Gesellschaften. Der Großteil der Mitteilungen stammt von Unternehmen aus Nordamerika, Großbritannien und den nordeuropäischen Ländern.
 
09.12.25 - 03:36
Minim Martap Development Update (GlobeNewswire EN)
 
Highlights...
09.12.25 - 03:12
Rio2 Announces Upsize of Previously Announced Bought Deal Financing to C$166 Million (GlobeNewswire EN)
 
VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Rio2 Limited (“Rio2” or the “Company”) (TSX: RIO; OTCQX: RIOFF; BVL: RIO) is pleased to announce that due to strong investor demand, the Company, Raymond James Ltd., (“Raymond James”), Stifel Nicolaus Canada Inc. (“Stifel”), and BMO Nesbitt Burns Inc. (“BMO”), the co-lead underwriters and joint bookrunners (collectively, the “Underwriters”) have upsized the previously announced “bought deal” financing from C$140 million to approximately C$166 million, or approximately US$120 million (the “Equity Financing”). Under the Equity Financing, the Underwriters have agreed to purchase, on a “bought deal” basis, 74,865,000 Subscription Receipts of the Company (“Subscription Receipts”) at a price of $2.22 per Subscription Receipts (the “Issue Price”) for gross proceeds of C$166,200,300....
09.12.25 - 03:06
Latest Data of InnoCare′s Novel BCL2 Inhibitor Presented at the 67th Annual Meeting of the American Society of Hematology (ASH) (GlobeNewswire EN)
 
The study of mesutoclax in the treatment of r/r MCL was selected for oral presentation, while the CLL/SLL and AML studies were chosen for poster....
09.12.25 - 02:33
EnWave to Report Fourth Quarter and Annual 2025 Financial Results on December 15, 2025 and Host Investor Conference Call  (GlobeNewswire EN)
 
VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the "Company") announced today it will report its financial results for the fourth quarter and the year ended September 30, 2025 on Monday, December 15, 2025 before the market opens. The financial statements and MD&A will be available on SEDAR at www.sedarplus.ca and on the Company's website....
09.12.25 - 02:33
Cygnus Metals Limited: Issue of Performance Rights (GlobeNewswire EN)
 
TORONTO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cygnus Metals Limited (“Cygnus” or the “Company”) advises that it issued an aggregate of 202,500 performance rights (“Performance Rights”) to employees on 27 November 2025 under the Company's Omnibus Equity Incentive Plan (“Plan”)....
09.12.25 - 02:33
Netcapital Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
 
BOSTON, MA, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Netcapital Inc. (Nasdaq: NCPL, NCPLW) (the “Company”), a digital private capital markets ecosystem, announced today the grant of an inducement restricted stock award of 1,000,000 shares of common stock (“Restricted Stock Award”) to a new employee under the Netcapital Inc. 2023 Omnibus Equity Incentive Plan (the “Plan”). The Restricted Stock Award was granted as an inducement under the Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4)....
09.12.25 - 02:18
Monument Mining Announces Results of Annual General Meeting of Shareholders (GlobeNewswire EN)
 
VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Monument Mining Limited (TSX-V: MMY and FSE: D7Q1) (“Monument” or the “Company”) is pleased to announce the results from its Annual General Meeting of shareholders (the “AGM”) held on December 08, 2025, in Vancouver, B.C....
09.12.25 - 02:03
Brookfield Corporation Announces Pricing of C$1 Billion of Medium-Term Notes (GlobeNewswire EN)
 
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION TO THE UNITED STATES...
09.12.25 - 01:48
ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP (GlobeNewswire EN)
 
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it presented four year follow-up data from its randomized controlled, registrational Phase II study of Olverembatinib in patients with tyrosine kinase inhibitor (TKI)-resistant/intolerant chronic-phase chronic myeloid leukemia (CML-CP), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. Building on results released in an oral presentation at ASH 2023, these data reaffirm Olverembatinib's differentiated long-term efficacy and safety....
09.12.25 - 01:48
ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60% (GlobeNewswire EN)
 
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the first dataset from the global registrational Phase III study (POLARIS-1) of the company's novel, investigational drug, Olverembatinib (HQP1351), in combination with low-intensity chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida....
09.12.25 - 01:48
ASH 2025 | Updated Data for Ascentage Pharma′s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment (GlobeNewswire EN)
 
ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development, and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has presented the latest data on Olverembatinib, the Company's novel drug, in second-line treatment of patients with chronic myeloid leukemia (CML) in chronic-phase (-CP), in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting, being held in Orlando, Florida. This presentation provided an update on the results released in an oral presentation at ASH 2024 and featured data from a longer follow-up on efficacy and safety....
09.12.25 - 01:45
RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO (GlobeNewswire EN)
 
RetinalGenix signs agreement to hire M. Cory Zwerling as its chief financial officer and interim chief operating officer, effective January 1, 2026...
09.12.25 - 01:24
Star Group, L.P. Reports Fiscal 2025 Full Year and Fourth Quarter Results (GlobeNewswire EN)
 
STAMFORD, Conn., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Star Group, L.P. (the "Company" or "Star") (NYSE:SGU), a home energy distributor and services provider, today announced financial results for its fiscal 2025 full year and fourth quarter, the three months ended September 30, 2025....
09.12.25 - 00:57
UPDATE - Broadway Star Morgan Dudley Joins Stargaze as Creative Advisor (GlobeNewswire EN)
 
Return Marks Full-Circle Moment for Scenebot Stage Discovery Return Marks Full-Circle Moment for Scenebot Stage Discovery...
09.12.25 - 00:33
“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer′s Disease Included in China′s Commercial Insurance Innovative Drug List (GlobeNewswire EN)
 
TOKYO and CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that anti-Aβ protofibril* antibody “LEQEMBI®” (brand name in China: “乐意保®”, generic name: lecanemab), has been included in the “Commercial Insurance Innovative Drug List” (Chinese: 商业健康保险创新药品目录), recently introduced by the National Healthcare Security Administration (NHSA) of China. The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer's Disease (AD) treatment in China....
09.12.25 - 00:03
AI UltraProd Announces U.S. Market Entry with Strategic Focus on High-Growth ADU Sector (GlobeNewswire EN)
 
SecureTech Backing Enables AI UltraProd's U.S. Accessory Dwelling Unit Beachhead; 2026 Rollout and Expansion Strategy...
08.12.25 - 23:27
Transocean Ltd. Announces $130 Million Award for Ultra-Deepwater Drillship (GlobeNewswire EN)
 
STEINHAUSEN, Switzerland, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) (“Transocean”) today announced the execution of a six-well contract in Australia with an undisclosed operator for the Deepwater Skyros. The estimated 320-day campaign is expected to commence in the first quarter of 2027 and contribute approximately $130 million in backlog, excluding compensation for mobilization and demobilization. The award includes priced options that, if fully exercised, could keep the drillship working in Australia into early 2030....
08.12.25 - 23:15
Mawson Receives Final Order for Arrangement with First Nordic Metals (GlobeNewswire EN)
 
VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Mawson Finland Limited (“Mawson” or the “Company”) (TSX-V: MFL) is pleased to announce that the Ontario Superior Court of Justice (Commercial List) has granted the final order (the "Final Order") in connection with the proposed business combination of Mawson and First Nordic Metals Corp. (TSX-V: FNM, FNSE: FNMC SDB, OTCQX: FNMCF, FRA: HEG0) (“First Nordic”), pursuant to which it is proposed that First Nordic will acquire all of the outstanding common shares of Mawson by way of a plan of arrangement (the “Arrangement”), pursuant to the terms and subject to the conditions of the arrangement agreement between Mawson and First Nordic dated September 14, 2025. As previously announced, the Arrangement was overwhelmingly approved by Mawson's shareholders at a special meeting held on December 4, 2025 (the "Meeting")...
08.12.25 - 23:03
Nayax Announces Preliminary Results of Notes and Warrants Offering in Israel to Qualified Investors (GlobeNewswire EN)
 
HERZLIYA, Israel, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX) (the “Company”) announced today, further to its announcement of December 7, 2025, that the Company completed in Israel a tender to qualified investors as defined under the Israeli Securities Law, 1968 (“Qualified Investors”) of notes, by expanding its Series A Notes, and Series 1 Warrants (the “Notes” and the “Warrants”, respectively and together, the “Securities”)....
08.12.25 - 23:03
Interfor Announces Appointment of Chief Financial Officer; Chief Operating Officer (GlobeNewswire EN)
 
BURNABY, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- INTERFOR CORPORATION (“Interfor” or the “Company”) (TSX: IFP) announced today that it has made several leadership changes. Mike Mackay has been appointed Executive Vice President & Chief Financial Officer, effective December 8, 2025. Mr. Mackay, who joined Interfor in 2015, has held several leadership roles in the Company's finance organization, most recently serving as Vice President, Corporate Development & Treasury. Mr. Mackay will succeed Rick Pozzebon, who will be leaving Interfor to pursue other opportunities....
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ist das Maisfeld fern vom Haus, fressen die Vögel die Frucht. - Sprichwort Pygmäen
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!